Occurrence of Cold Urticaria during Venom Desensitization

Anfosso-Capra, Francine; Philip-Joët, F.; Reynaud‐Gaubert, Martine; Arnaud, A.

doi:10.1159/000248047

Cited by 10 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports have described localized 2 , 3 ) or generalized 4 ) cases of cold urticaria during SIT. Rotne 1 ) reported cases with exercise-induced urticaria at the SIT site two to three weeks after the last allergen injection.…”

Section: Discussionmentioning

confidence: 99%

Late Local Urticaria as a Long-term Sequela of Allergen-Specific Immunotherapy

Choi

Koh

Chung

et al. 2004

Korean J Intern Med

View full text Add to dashboard Cite

Local reaction to allergen-specific immunotherapy (SIT) usually appears within 30 minutes, but cases with exercise-induced urticaria at the SIT site 2–3 weeks after the last allergen injection have been reported. A 28-year-old man was treated with house dust mite-SIT for 5 years, due to asthma when he was an 11-year-old boy. On a treadmill exercise test for 50 minutes, erythema, swelling, and pruritus occurred at the SIT site, which lasted for one hour. There was no evidence of complement activation, and the skin biopsy specimens showed no apparent difference between the lesion and normal sites in the distribution of inflammatory cells and in mast cell degranulation. However, the morphine, but not the histamine, skin test responses were increased after the exercise. There must be a remaining long-term sequela of the SIT, including an increased releasability of mast cells, even after more than 10 years.

show abstract

Section: Discussionmentioning

confidence: 99%

Late Local Urticaria as a Long-term Sequela of Allergen-Specific Immunotherapy

Choi

Koh

Chung

et al. 2004

Korean J Intern Med

View full text Add to dashboard Cite

show abstract

“…Despite the daily administration of high-dose of inhaled combined fluticasone/salmeterol (2000/ 200 lg) and montelukasm tablet (10 mg), the patient suffered constantly from respiratory symptoms during work. Baseline forced expiratory volume in 1 s (FEV 1 ) was 59% of predicted normal value and so the patient met the Global Initiative for Asthma definition of severe persistent asthma (3). Taking into account the body weight and total serum IgE level at baseline, the dose of 375 mg of omalizumab was administered by means of subcutaneous injection twice a month.…”

mentioning

confidence: 99%